The Global Animal Sedatives Market is likely to grow by the end of 2026 due to curing of diseases of the afflicted animals, treatment of their wounds, and pain management in animals, states Fortune Business Insights, in a report titled, “Animal Sedatives Market Size, Share and Global Trend By Drug Class (Phenothiazines, Benzodiazepines, 2 adrenergic Receptor Agonists, Butyrophenones), By Application (Surgical, Diagnosis, Clinical Research Studies), By Route Of Administration (Oral, Parenteral), By Animal Type (Small, Large), By Distribution Channel (Veterinary Hospital, Clinic Pharmacies, Veterinary Retail Pharmacies, Veterinary Online Pharmacies), and Geographical Forecast till 2026.”
Animal sedatives are also beneficial for the diagnosis of cancers in animals and prevention of the spread of zoonotic diseases. The report classifies the global animal sedatives market into six segments, namely, drug class, application, route of administration, animal type, distribution channel, and geography. The drug class is further segmented into phenothiazines, benzodiazepines, α2‐adrenergic receptor agonists, butyrophenones, and others.
Some of the Main Key Players Covered in the Report
- Bayer AG
- Boehringer Ingelheim International GmbH
- Intervet Inc.
Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/animal-sedatives-market-100454
North America and Europe are Anticipated to Hold a Notably Large Market Share
The global market is geographically segmented into Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. Amongst these, North America is projected to hold a significant share of global animal sedatives market, followed by Europe.
A rise in the prevalence of zoonotic diseases, adoption of animal sedatives, and increasing investment in medical research for animals are the three main causes of the growth of animal sedatives market in North America and Europe. Medical researches on animals are conducted to study pharmacodynamics and pharmacokinetics of drugs.
Key Players to Adopt Innovative Strategies to Lead Market
Zoetis, the world’s largest producer of vaccines and medicines for pets, launched SILEO (dexmedetomidine oromucosal gel) in May 2016, for dogs that suffer from noise aversions. SILEO is the first and the only medication that is approved by the FDA for the treatment of dogs. Earlier, in August 2015, Zoetis received approval from FDA for SIMBADOL, a buprenorphine injection for cats to control postoperative pain for 24 hours.
Some of the major companies that are present in the global animal sedatives market are Zoetis, Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Intervet Inc., and other key players.
More Trending Topics from Future Business Insights: